Big Pharma and Private Equity firms invest in drug discovery companies and biotech startups due to the high cost of R&D and better ROI. By Michael Megarit. A recent Deloitte report reveals that the R&D returns of the 15 leading US biopharma companies are just 2.5% in 2020, down from a [...]